Drug General Information
Drug ID	D0E0AS
Former ID	DIB000957
Drug Name	(S)-oxybutynin
Indication	Urinary incontinence [ICD9: 788.3; ICD10:N39.3, N39.4, R32]		Phase 2	[525400]
Company	Sepracor
Structure		Download 2D MOL 3D MOL
Target and Pathway
Target(s)	Muscarinic acetylcholine receptor M1	Target Info	Antagonist	[530541]
KEGG Pathway	Calcium signaling pathway
	cAMP signaling pathway
	Neuroactive ligand-receptor interaction
	PI3K-Akt signaling pathway
	Cholinergic synapse
	Regulation of actin cytoskeleton
PANTHER Pathway	Alzheimer disease-amyloid secretase pathway
	Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
	Muscarinic acetylcholine receptor 1 and 3 signaling pathway
Reactome	Muscarinic acetylcholine receptors
	G alpha (q) signalling events
WikiPathways	Monoamine GPCRs
	Calcium Regulation in the Cardiac Cell
	Regulation of Actin Cytoskeleton
	GPCRs, Class A Rhodopsin-like
	Gastrin-CREB signalling pathway via PKC and MAPK
	Secretion of Hydrochloric Acid in Parietal Cells
	GPCR ligand binding
	GPCR downstream signaling
References
Ref 525400	A phase 2, randomized, double-blind, efficacy and safety study of oxybutynin vaginal ring for alleviation of overactive bladder symptoms in women. J Urol. 2014 Apr;191(4):1014-21.
Ref 530541	Enantiomers of oxybutynin: in vitro pharmacological characterization at M1, M2 and M3 muscarinic receptors and in vivo effects on urinary bladder contraction, mydriasis and salivary secretion in guinea pigs. J Pharmacol Exp Ther. 1991 Feb;256(2):562-7.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.